Endometrial cancer is usually endometrioid adenocarcinoma. Typically, postmenopausal vaginal bleeding occurs. Diagnosis is by biopsy. Staging is surgical. Treatment requires hysterectomy, bilateral salpingo-oophorectomy, usually pelvic and para-aortic lymph node dissection, and excision of all tissue likely to be involved. For advanced cancer, radiation, hormone, or cytotoxic therapy is usually indicated.
Endometrial cancer is more common in developed countries where the diet is high in fat. In the US, this cancer is the 4th most common cancer among women, affecting 1 in 50, and may become even more common as prevalence of the metabolic syndrome increases. In 2013, it was estimated that endometrial cancer was diagnosed in 49,560 women and that 8190 women died of this cancer.
Endometrial cancer affects mainly postmenopausal women. Mean patient age at diagnosis is 61 yr. Most cases are diagnosed in women aged 50 to 60 yr; 92% of cases occur in women > 50 yr.
Major risk factors are
Other risk factors include
Unopposed estrogen (high circulating levels of estrogen with no or low levels of progesterone) may be associated with obesity, polycystic ovary syndrome, nulliparity, late menopause, estrogen-producing tumors, anovulation (ovulatory dysfunction), and estrogen therapy without progesterone. Heredity contributes to endometrial cancer in up to 10% of cases; about half of these cases occur in families with hereditary nonpolyposis colorectal cancer (Lynch syndrome).
Endometrial cancer is usually preceded by endometrial hyperplasia. Adenocarcinomas account for > 80% of endometrial cancers. Endometrial adenocarcinoma is commonly classified into 2 types.
Type I tumors are more common, are commonly estrogen-responsive, and are usually diagnosed in younger, obese, or perimenopausal women. These tumors are usually low-grade. Endometroid is the most common histology. These tumors may show microsatellite instability and have mutations in PTEN, PIK3CA, KRAS, and CTNNBI.
Type II tumors are usually high-grade (eg, serous or clear cell histology). They tend to occur in older women. About 10 to 30% have p53 mutations. Up to 10% of endometrial adenocarcinomas are type II.
The cancer may spread from the surface of the uterine cavity to the cervical canal; through the myometrium to the serosa and into the peritoneal cavity; via the lumen of the fallopian tube to the ovary, broad ligament, and peritoneal surfaces; via the bloodstream, leading to distant metastases; or via the lymphatics. The higher (more undifferentiated) the grade of the tumor, the greater the likelihood of deep myometrial invasion, pelvic or para-aortic lymph node metastases, or extrauterine spread.
Symptoms and Signs
Most (> 90%) women have abnormal uterine bleeding (eg, postmenopausal bleeding, premenopausal recurrent metrorrhagia); one third of women with postmenopausal bleeding have endometrial cancer. A vaginal discharge may occur weeks or months before postmenopausal bleeding.
The following suggest endometrial cancer:
If cancer is suspected, outpatient endometrial biopsy is done; it is > 90% accurate. Endometrial sampling is also recommended for women with abnormal bleeding, particularly those > 40 yr. If results are inconclusive or suggest cancer (eg, complex hyperplasia with atypia), outpatient fractional D & C with hysteroscopy is done. An alternative is transvaginal ultrasonography; however, a histologic diagnosis is required.
Once cancer is diagnosed, pretreatment evaluation includes serum electrolytes, kidney and liver function tests, CBC, chest x-ray, and ECG. Pelvic and abdominal CT are also done to check for extrauterine or metastatic cancer in patients with any of the following:
Staging is based on histologic differentiation (grade 1 [least aggressive] to 3 [most aggressive]) and extent of spread, including invasion depth, cervical involvement (glandular involvement vs stromal invasion), and extrauterine metastases (Table 3: Staging of Endometrial Carcinoma). Staging is surgical and includes peritoneal fluid cytology, exploration of the abdomen and pelvis, and biopsy or excision of suspect extrauterine lesions. Pelvic and para-aortic lymph nodes are removed. During staging, a total abdominal hysterectomy and bilateral salpingo-oophorectomy are done. Surgical staging can be done via laparotomy, laparoscopy, or a robotics surgical system.
Prognosis is worse with higher-grade tumors, more extensive spread, and older patient age. Average 5-yr survival rates are
Overall, 63% of patients are cancer-free ≥ 5 yr after treatment.
If cancer appears to be stage I/grade 1 without deep myometrial invasion, the probability of unrecognized lymph node metastasis is < 2%. Treatment is usually total hysterectomy and bilateral salpingo-oophorectomy via laparotomy, laparoscopy, or robotics.
For grade 1 or 2 with ≥ 50% myometrial invasion or grade 3, complete pelvic and para-aortic lymphadenectomy is also done. Whether the extent of para-aortic node dissection should reach the inferior mesenteric artery vs the renal vessels remains a topic of debate.
Stage II or III cancer requires pelvic radiation therapy with or without chemotherapy. Treatment of stage III cancer must be individualized, but surgery is an option; generally, patients who undergo combined surgery and radiation therapy have a better prognosis. Except in patients with bulky parametrial disease, a total abdominal hysterectomy and bilateral salpingo-oophorectomy should be done.
Treatment of stage IV is variable and patient dependent but typically involves a combination of surgery, radiation therapy, and chemotherapy. Occasionally, hormonal therapy should also be considered.
Hormone therapy with a progestin causes regression for up to 3 yr in 20 to 25% of patients. Pulmonary, vaginal, and mediastinal metastases may regress. Treatment continues as long as the response is favorable.
Several cytotoxic drugs (particularly carboplatin plus paclitaxel) are effective. They are given mainly to women with metastatic or recurrent cancer. Another option is doxorubicin 60 mg/m2 plus cisplatin 60 mg/m2 IV, overall response rate may be ≥ 50%.
Treatment of endometrial hyperplasia consists of progestins or surgery (eg, D & C), depending on the complexity of the lesion and the patient's desire to avoid hysterectomy. If young patients with grade 1 tumors and no myometrial invasion (documented by MRI) wish to preserve fertility, progestin alone is an option. About 46 to 80% of patients have a complete response within 3 mo on average. After 3 mo, patients should be evaluated via D & C rather than endometrial biopsy.
Last full review/revision May 2013 by Pedro T. Ramirez, MD; David M. Gershenson, MD
Content last modified September 2013